Sub-chronic treatment with classical but not atypical antipsychotics produces morphological changes in rat nigro-striatal dopaminergic neurons directly related to "early onset" vacuous chewing

Eur J Neurosci. 2002 Apr;15(7):1187-96. doi: 10.1046/j.1460-9568.2002.01944.x.

Abstract

In the present work, we investigated if an impairment of dopaminergic neurons after subchronic haloperidol treatment might be a possible physiopathologic substrate of the "early onset" vacuous chewing movements (VCMs) in rats. For this purpose, different antipsychotics were used to analyse a possible relationship between VCMs development and morphological alterations of tyrosine-hydroxylase-immunostained (TH-IM) neurons. Rats treated twice a day with haloperidol displayed a significant increase of VCMs that was both time- (2-4 weeks) and dose (0.1-1 mg/kg) dependent. Immunocytochemical analysis showed a shrinkage of TH-IM cell bodies in substantia nigra pars compacta and reticulata and a reduction of TH-immunostaining in the striatum of haloperidol treated rats with the arising of VCMs. No differences were observed in TH-IM neurons of ventral tegmental area and nucleus accumbens vs. control rats. The atypical antipsychotics risperidone (2 mg/kg, twice a day), amisulpride (20 mg/kg, twice a day) and clozapine (10 mg/kg, twice a day) did not produce any nigro-striatal morphological changes or VCMs. TH-IM nigro-striatal neuron morphological alterations and VCMs were still present after three days of withdrawal in rats treated for four weeks with haloperidol (1 mg/kg). Both the main morphological changes and the behavioural correlate disappeared after three weeks of withdrawal. These results suggest that haloperidol induces a morphological impairment of the dopaminergic nigro-striatal neurons which is directly associated with the arising, permanency and disappearance of VCMs in rats.

MeSH terms

  • Amisulpride
  • Animals
  • Antipsychotic Agents / toxicity*
  • Clozapine / toxicity
  • Dopamine / metabolism
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Dyskinesia, Drug-Induced / metabolism
  • Dyskinesia, Drug-Induced / pathology*
  • Dyskinesia, Drug-Induced / physiopathology
  • Haloperidol / toxicity*
  • Male
  • Mastication / drug effects
  • Mastication / physiology
  • Neostriatum / drug effects*
  • Neostriatum / metabolism
  • Neostriatum / pathology
  • Nerve Degeneration / chemically induced*
  • Nerve Degeneration / metabolism
  • Nerve Degeneration / pathology
  • Neural Pathways / drug effects*
  • Neural Pathways / metabolism
  • Neural Pathways / pathology
  • Neurons / drug effects
  • Neurons / metabolism
  • Neurons / pathology
  • Rats
  • Rats, Sprague-Dawley
  • Risperidone / toxicity
  • Substance Withdrawal Syndrome / metabolism
  • Substance Withdrawal Syndrome / pathology
  • Substance Withdrawal Syndrome / physiopathology
  • Substantia Nigra / drug effects*
  • Substantia Nigra / metabolism
  • Substantia Nigra / pathology
  • Sulpiride / analogs & derivatives*
  • Sulpiride / toxicity

Substances

  • Antipsychotic Agents
  • Sulpiride
  • Amisulpride
  • Clozapine
  • Haloperidol
  • Risperidone
  • Dopamine